Skip to main content

Elazzouzi Amy's Form 4 filing

Aura Biosciences, Inc. (AURA) · filed Aug 18, 2025

Accession no.
0000950170-25-109767
Filed
Aug 18, 2025
Trade date
Aug 18, 2025
Filing delay
Same day
Rule 10b5-1 plan
Not checked

This filing lists 8 non-derivative transactions and 7 derivative transactions. Open-market sales total $51.7K. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Elazzouzi AmyCIK 0002042910Officer (Senior Vice President, Finance)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 18, 2025Common StockMOption exerciseAcquired+2,554$5.07+$12,948.7883,935Direct
Aug 18, 2025Common StockMOption exerciseAcquired+1,094$5.48+$5,995.1285,029Direct
Aug 18, 2025Common StockMOption exerciseAcquired+547$5.48+$2,997.5685,576Direct
Aug 18, 2025Common StockMOption exerciseAcquired+547$5.21+$2,849.8786,123Direct
Aug 18, 2025Common StockMOption exerciseAcquired+4,744$2.74+$12,998.5690,867Direct
Aug 18, 2025Common StockMOption exerciseAcquired+1,094$3.16+$3,457.0491,961Direct
Aug 18, 2025Common StockMOption exerciseAcquired+2,319$4.25+$9,855.7594,280Direct
Aug 18, 2025Common StockSSaleDisposed−7,722$6.70F2−$51,737.486,558Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 18, 2025Common StockMOption exerciseDisposed−2,554$0.00$00Direct
Aug 18, 2025Common StockMOption exerciseDisposed−1,094$0.00$00Direct
Aug 18, 2025Common StockMOption exerciseDisposed−547$0.00$00Direct
Aug 18, 2025Common StockMOption exerciseDisposed−547$0.00$00Direct
Aug 18, 2025Common StockMOption exerciseDisposed−4,744$0.00$00Direct
Aug 18, 2025Common StockMOption exerciseDisposed−1,094$0.00$00Direct
Aug 18, 2025Common StockMOption exerciseDisposed−2,319$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.57 to $6.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)